Vanguard Fiduciary Trust
MRKR icon

Vanguard Fiduciary Trust’s Marker Therapeutics MRKR Stock Holding History

Vanguard Fiduciary Trust’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Hold
87,269
– – ﹤0.01% 3691
2026
Q1 		$113K Buy
+87,269
New +$138K ﹤0.01% 3686

Other funds holding MRKR

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Fiduciary Trust's MRKR Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Marker Therapeutics (MRKR) position steady in Q2 2026 at 87,269 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #3691.

Vanguard Fiduciary Trust first reported a position in MRKR in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Vanguard Fiduciary Trust held 87,269 shares of Marker Therapeutics worth $128K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Marker Therapeutics share count unchanged in Q2 2026.
  • Marker Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3691 holding.
  • Vanguard Fiduciary Trust first reported a position in Marker Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.